Adagene Reports H1 2026 Results: $127.9M Cash, Runway into Late 2028, Muzastotug Phase 2 Data Expected 1H 2027
ADAG has more than doubled off its 52-week low of $1.3.
Summary
Adagene reported H1 2026 financials with $127.9M in cash, runway into late 2028, and advancing clinical programs for muzastotug in colorectal and liver cancers, with pivotal data expected in 2027.
Key Events · Earnings and Guidance · ADAG
-
Cash Runway Extended to Late 2028
Cash and equivalents rose to $127.9 million as of June 30, 2026, from $74.5 million at year-end 2025, driven by a $70 million public offering in April 2026. Management expects this funds operations into late 2028.
-
Muzastotug Phase 2 Data Expected 1H 2027
The randomized Phase 2 trial in MSS CRC is enrolling well, with results expected in the first half of 2027. A potential registration trial could begin later in 2027 once the recommended dose is established.
-
New Collaborations Validate Platform
Sanofi initiated a global Phase 1/2 basket trial combining muzastotug with a next-generation IO agent. Incyte established a clinical collaboration to evaluate muzastotug with its TGFβR2xPD-1 bispecific antibody, with a Phase 1 study expected to start later this year.
-
Strengthened Clinical Advisory Board
Peter Lebowitz, M.D., Ph.D., former Global Head of Oncology R&D at Johnson & Johnson, joined the Scientific and Strategic Advisory Board to guide muzastotug's clinical development and registration strategy.
Analysis · ADAG · Life Sciences
Adagene's H1 2026 update shows a strengthened balance sheet with $127.9 million in cash, extending runway into late 2028 — critical for a clinical-stage biotech without product revenue. The lead asset muzastotug continues to show compelling efficacy in MSS CRC and HCC, with a randomized Phase 2 readout expected in the first half of 2027 and a potential registration trial later that year. New collaborations with Sanofi and Incyte validate the platform, while the addition of a former J&J oncology head to the advisory board adds clinical development expertise. The net loss widened to $16.4 million from $13.5 million, driven by increased R&D spending, but the cash position and pipeline momentum outweigh the near-term burn.
At the time of this filing, ADAG was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.3M. The 52-week trading range was $1.30 to $4.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.